| MeSH term | MeSH ID | Detail |
|---|---|---|
| Dyslipidemias | D050171 | 7 associated lipids |
| Hashimoto Disease | D050031 | 1 associated lipids |
| Hyperparathyroidism, Primary | D049950 | 1 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hypertension, Pregnancy-Induced | D046110 | 2 associated lipids |
| Scleroderma, Limited | D045745 | 1 associated lipids |
| Glucose Metabolism Disorders | D044882 | 3 associated lipids |
| Malnutrition | D044342 | 6 associated lipids |
| Irritable Bowel Syndrome | D043183 | 8 associated lipids |
| Mastocytoma | D034801 | 3 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
| Quinn JM et al. | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | 2000 | J. Bone Miner. Res. | pmid:10934644 |
| Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
| Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
| López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
| Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
| Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
| Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
| Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
| Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |